Genscript Biotech Corporation (HKG:1548)
Hong Kong · Delayed Price · Currency is HKD 31.60
-1.28 (-3.89%)
Oct 23, 2026, 4:08 PM HKT
Genscript Biotech Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Genscript Biotech stock has a consensus rating of "Strong Buy" and an average price target of $32.95. The average 1-year stock price forecast is 4.27% higher than the current stock price, while the lowest is $15.92 (-49.62%) and the highest is $42.65 (+34.97%).
Price Target: $32.95 (+4.27%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Sep 18, 2026.
Analyst Ratings
The average analyst rating for Genscript Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst CSC Financial No rating | CSC Financial | Buy Maintains $48.22 → $55.59 | Buy | Maintains | $48.22 → $55.59 | +75.92% | Sep 18, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $41.00 | Buy | Maintains | $41.00 | +29.75% | Sep 17, 2026 |
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $34.51 | Buy | Maintains | $34.51 | +9.21% | Aug 21, 2026 |
| Jefferies | Jefferies | Buy Maintains $30.00 | Buy | Maintains | $30.00 | -5.06% | Aug 20, 2026 |
Unknown Analyst BOCOM International Holdings Company No rating | BOCOM International Holdings Company | Buy Maintains $32.20 | Buy | Maintains | $32.20 | +1.90% | Aug 20, 2026 |
Financial Forecast
Revenue This Year
889.41M
from 959.53M
Decreased by -7.31%
Revenue Next Year
1.10B
from 889.41M
Increased by 23.50%
EPS This Year
0.03
from 0.11
Decreased by -71.46%
EPS Next Year
0.05
from 0.03
Increased by 66.67%
EPS and Forward PE are based on non-GAAP adjusted numbers.